GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aileron Therapeutics Inc (NAS:ALRN) » Definitions » Sloan Ratio %

Aileron Therapeutics (Aileron Therapeutics) Sloan Ratio % : 0.00% (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aileron Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Aileron Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 was 0.00%.

As of Mar. 2024, Aileron Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Aileron Therapeutics Sloan Ratio % Historical Data

The historical data trend for Aileron Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aileron Therapeutics Sloan Ratio % Chart

Aileron Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only -0.31 -43.40 69.11 -131.43 -11.43

Aileron Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -140.00 -164.53 -157.31 -11.43 -

Competitive Comparison of Aileron Therapeutics's Sloan Ratio %

For the Biotechnology subindustry, Aileron Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aileron Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aileron Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Aileron Therapeutics's Sloan Ratio % falls into.



Aileron Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Aileron Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-15.732--19.808
-16.196)/106.008
=-11.43%

Aileron Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Mar. 2024 )
=(-18.066--20.418
-8.946)/99.192
=-6.65%

Aileron Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -1.787 (Jun. 2023 ) + -1.827 (Sep. 2023 ) + -7.339 (Dec. 2023 ) + -7.113 (Mar. 2024 ) = $-18.07 Mil.
Aileron Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -3.116 (Jun. 2023 ) + -1.64 (Sep. 2023 ) + -10.391 (Dec. 2023 ) + -5.271 (Mar. 2024 ) = $-20.42 Mil.
Aileron Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 8.5 (Jun. 2023 ) + 0.542 (Sep. 2023 ) + -0.096 (Dec. 2023 ) + 0 (Mar. 2024 ) = $8.95 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aileron Therapeutics  (NAS:ALRN) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Aileron Therapeutics has a Sloan Ratio of 0.00%, indicating the company is in the safe zone and there is no funny business with accruals.


Aileron Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Aileron Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aileron Therapeutics (Aileron Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
285 Summer Street, Unit 101, Boston, MA, USA, 02210
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects.
Executives
James Brian Windsor officer: See Remarks 2600 VIA FORTUNA, SUITE 360, AUSTIN TX 78746
William Fairey director C/O CHEMOCENTRYX, INC., 850 MAUDE AVE., MOUNTAIN VIEW CA 94043
Alan A Musso director FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Susan L. Drexler officer: See Remarks 630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Muneer A Satter 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Reinhard J. Ambros director C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Von Rickenbach Josef H director C/O PAREXEL INTERNATIONAL CORPORATION, WALTHAM MA 02451-1163
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Vojo Vukovic officer: SVP, Chief Medical Officer C/O SYNTA PHARMACEUTICALS CORP., 45 HARTWELL AVENUE, LEXINGTON MA 02421
Kathryn Gregory officer: SVP, Chief Business Officer 305 THAYER POND ROAD, WILTON CT 06897
William Mckee director
Nolan Howard Sigal director 941 BERRY AVENUE, LOS ALTOS CA 94024
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Rick Wanstall officer: VP, Finance and Operations C/O AILERON THERAPEUTICS, INC., 490 ARSENAL WAY, WATERTOWN MA 02472
Longenecker John P Phd officer: President and CEO 10445 PACIFIC CENTER CT, SAN DIEGO CA 92121

Aileron Therapeutics (Aileron Therapeutics) Headlines

From GuruFocus

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

By Value_Insider Value_Insider 11-30-2022

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

By GuruFocusNews GuruFocusNews 06-22-2022